Immunotherapy with simvastatin and chemo for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of immunotherapy, simvastatin (a cholesterol drug), and standard chemotherapy for advanced colorectal cancer that has not been treated before. The goal is to see if adding simvastatin can help the immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced colorectal cancer that has spread.
- You have not received any prior chemotherapy or targeted therapy for your cancer.
- You are between 18 and 75 years old.
- You are in good overall health (able to care for yourself).
- Your blood counts, liver and kidney function are within acceptable levels.
- You do not have active brain metastases or uncontrolled heart conditions, bleeding problems, or blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two drugs—bevacizumab and adebrelimab—can help people with a specific type of colorectal cancer that has spread and is MSS-type. It's for patients who have already had standard chemotherapy and have tumors that show certain genetic features.
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of four drugs (chidamide, a PD-1 inhibitor, bevacizumab, and XELOX chemotherapy) for people with metastatic colorectal cancer that has not been treated before. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus chemotherapy for people with a specific type of colorectal cancer that hasn't spread to the liver. It may be an option if your cancer is mismatch repair stable (MSS or pMMR) and has progressed after initial treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a targeted therapy) and alternating chemotherapy regimens as a first treatment for advanced colorectal cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.